Serial No. : 09/691,776

Filed: October 18, 2000

Page 17

D. Remarks

Reconsideration and allowance in view of the amendments made and comments which follow are respectfully requested.

Claims 1-22 are pending in this application. Claim 1 is being amended. New claims 23-26 are being added. Claims 1-26 are now pending.

In the Office Action, claims 1-22 were rejected under 35 U.S.C. 103(a) as being allegedly unpatentable over MacKinnon (Radiology, 1997) in view of Somorjai (Magnetic Resonance in Medicine, 1995). The Examiner stated that in the paper MacKinnon discusses fineneedle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy to determine whether invasive breast cancer can be distinguished from benign lesions with proton magnetic resonance (MR) spectroscopy ex vivo on the basis of altered cellular chemistry. The Examiner stated that the MacKinnon paper concluded that proton MR spectroscopy of fineneedle biopsy specimens provides objective diagnostic information that complements findings of conventional preoperative investigations of breast lesions. The Examiner stated that relative to the instant claims is the paragraph bridging the column 2-3 of page 664. The Examiner stated that the last sentence of the paragraph cites the Somorjai reference and teaches that the multivariate techniques of the reference are "likely to improve sensitivity and specificity" of the analysis.

The Examiner stated that in the paper Somorjai presents computerized consensus diagnosis as a classification strategy for the robust analysis of $^1\mathrm{H}$ MR spectra of thyroid neoplasms. The

Applicants

Carolyn E. Mountford et al.

Serial No.

: 09/691,776

Filed

October 18, 2000

Page 18

Examiner stated that they developed and applied new classification strategy called computerized consensus diagnosis (CCD) to provide robust, reliable classification of biomedical The Examiner stated that the strategy involves the crossvalidated training of several classifier of diverse conceptual and methodological origin on the same data, and appropriately combining their outcomes using Linear Discriminant Analysis as independent classifiers on two spectral regions, and chose the median of the six classification outcomes as the consensus.

The Examiner stated that it would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate the multivariate analysis methodology of Somorjai into the MacKinnon analysis of breast tissues because of the statement by MacKinnon directing one of the Somorjai multivariate method as likely to provide improved results and the teaching of improved analysis results by Somorjai.

The Somorjai reference cited by the Examiner reports on earlier work of co-inventors herein, and applicants are familiar with this work.

The Somorjai reference does not disclose clause (c) of claim 1 which recites repeating the cross-validation of step (b) a plurality of times. Nowhere does Somorjai disclose repeating any cross-validation step.

Somorjai also fails to disclose clause (d) of claim 1, which recites obtaining a weighted average of the linear discriminant analysis (LDA) coefficients (obtained from step (c)) to obtain final classifier spectra.

Serial No. : 09/691,776

Filed : October 18, 2000

Page 19

For these reasons, Somorjai fails to disclose claim 1. For at least the same reasons, Somorjai also fails to disclose claim 9, 15 and 19.

Even if the MacKinnon and Somorjai references were combined as proposed by the Examiner, claim 1 is patentable at least because Somorjai fails to disclose the features discussed above.

In view of the foregoing, applicant urges that independent claims 1, 9, 15 and 19 are patentable over the prior art cited. New claims 23, 24, 25 and 26 are being added. These new claims track claims 1, 9, 15 and 19, respectively, but are not limited to breast tissue or biopsies of tissue. Applicant believes that these claims are patentable as well, at least for the same reasons given above in connection with claim 1.

In compliance with his duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the following references which are listed on the accompanying form PTO-1449 (Exhibit 1). These references are listed in the present application at the end of the specification before the claims. Copies of references numbered 3, 4, 5, 7, 8, 9, 14, 15, 16, 17, 19, 20, 21, 22, 24 and 25 are enclosed, and the remainder numbered 1, 2, 6, 10, 11, 12, 13, 18 and 23 are still being located.

- 1. Kitchen PR, McLennan R, Mursell A. Node-positive breast cancer: a comparison of clinical and pathological findings and assessment of axillary clearance. Australian & New Zealand Journal of Surgery 1980; 50:580-3.
- 2. Dixon JM, Senbanjo RO, Anderson TJ, mammography. Risk of

Serial No. : 09/691,776

Filed : October 18, 2000

Page 20

.

breast cancer based on age and mammographic interpretation Clinical Oncology 1984; 10:117-21.

3. Kerlikowske K, Grady D, Barclay J. Sickles EA, Ernster V. Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. [JAMA 1996;276:39-43].

- 4. Giard RW, Hermans J. The value of aspiration cytologic examination of the breast. A statistical review of the medical literature. Cancer 1992; 69:2104-10.
- 5. Delikatny EJ, Russell P, Hunter JC, et al. Proton MR and human cervical neoplasia: ex-vivo spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma in-situ and other preinvasive lesions. Radiology 1993; 188:791-6.
- 6. Lean CL, Newland RC, Ende DA, Bokey EL, Smith IC, Mountford CE. Assessment of human colorectal biopsies by 1H MRS: correlation with histopathology. Magnetic Resonance in Medicine 1993; 30:525-33.
- 7. Russell P, Lean CL, Delbridge L, May GL, Dowd S, Mountford CE. Proton magnetic resonance and human thyroid neoplasia. I: Discrimination between benign and malignant neoplasms. American Journal of Medicine 1994; 96:383-8.
- 8. Rutter A, Hugenholtz H, Saunders JK, Smith IC. Classification of brain tumors by ex vivo 1H NMR spectroscopy. Journal of Neurochemistry 1995; 64:1655-61.

Serial No. : 09/691,776 Filed : October 18, 2000

Page 21

9. Mountford CE, Lean CL, Hancock R, et al. Magnetic resonance spectroscopy detects cancer in draining lymph nodes. Invasion & Metastasis 1993; 13:57-71.

- 10. Somorjai RL, Dolenko B, Nikulin AK, et al. Classification of 1H MR spectra of human brain neoplasms: the influence of preprocessing and computerized consensus diagnosis on classification accuracy. Journal of Magnetic Resonance Imaging 1996; 6:437-44.
- 11. The Pathology reporting of Breast Cancer, Recommendations of the Australian Cancer Network. May 1977, The Stone Press, Epping NSW.
- 12. Efron B, Tibshirani RJ. An Introduction to the Bootstrap.

 Monograms of Statistics and Applied Probability. Vol. 57:

 Chapman Hill, New York, 1993.
- 13. Weidner N. Prognostic factors in breast carcinoma. Current Opinion in Obstetrics & Gynecology 1995; 7:4-9.
- 14. Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Annals of Surgery 1968; 168:337-56.
- 15. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for Tla breast carcinoma. Is it indicated? Cancer 1994; 73:664-7.
- 16. Chen YY, Schnitt SJ. Prognostic factors for patients with

Serial No. : 09/691,776

Filed: October 18, 2000

Page 22

breast cancers 1cm and smaller. Breast Cancer Research & Treatment 1998; 51:209-25.

- 17. Cady B. The need to reexamine axillary lymph node dissection in invasive breast cancer [editorial]. Cancer 1994; 73:505-8.
- 18. Beechey-Newman N. Sentinel node biopsy: a revolution in the surgical management of breast cancer? Cancer Treatment Reviews 1998; 24:185-203.
- 19. Hill AD, Mann GB, Borgen PI, Cody HS, 3rd. Sentinel lymphatic mapping in breast cancer. Journal of the American College of Surgeons 1999; 188:545-9.
- 20. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997; 79:1918-22.
- 21. Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis. Cancer 1994; 73:350-3.
- 22. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. Journal of Clinical Oncology 1989; 7:1239-51.
- 23. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival

Serial No. : 09/691,776

Filed: October 18, 2000

Page 23

in a large study with long-term follow-up. Histopathology 1994; 24:41-7.

24. De Laurentiis M, Gallo C, De Placido S, et al. A predictive index of axillary nodal involvement in operable breast cancer.

British Journal of Cancer 1996; 73:1241-7.

25. Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995; 76:1772-8.

A copy of a International Search Report, issued April 2, 2001 in connection with corresponding PCT International Application No. CA00/01238, is attached. Also attached is a copy of the PCT Written Opinion dated August 9, 2001.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invites the Examiner to telephone them at the number provided below.

Other than the \$55 one-month extension fee, \$180 fee for filing the Information Disclosure Statement, and the additional claims fee of \$196 (a check totaling \$431.00 for which is enclosed), no additional fee is deemed necessary in connection with the filing of this Response. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Applicants Serial No. Carolyn E. Mountford et al.

09/691,776

Filed Page 24

October 18, 2000

RECEIVED JUN 2 5 7003 GROUP 1700

Respectfully submitted,

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Peter J. Phillips

Reg. No. 29,691

Attorneys for Applicants Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036 (212) 278-0400

Registration No. 29,691

Peter J. Phillips